Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
David F McDermottJae Lyun LeeMarek ZiobroCristina SuarezPrzemyslaw LangiewiczVsevolod Borisovich MatveevPawel WiechnoRustem Airatovich GafanovPiotr TomczakFrederic PouliotFrede DonskovBoris Yakovlevich AlekseevSang Joon ShinGeorg Arnold BjarnasonDaniel CastellanoRachel Kloss SilvermanRodolfo F PeriniCharles SchlossMichael B AtkinsPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
First-line pembrolizumab monotherapy showed promising antitumor activity in nccRCC. The safety profile was similar to that observed in other tumor types.